CNBC's Karen Gilchrist discusses Novo Nordisk's new CEO and the pharma giant's move to cut its full-year guidance on weaker ...

Compounding pharmacies are crimping sales of Novo Nordisk's obesity drug Wegovy by making what are essentially copies of the ...

Pedersen, Stine Jacobsen and Maggie Fick COPENHAGEN (Reuters) -Investors wiped $70 billion off Novo Nordisk's market value on ...

Novo, which became Europe’s most valuable listed company following the launch of Wegovy in 2021, is now facing a reckoning as ...

Novo Nordisk's technical chart is displaying a largely bearish trend amid a profit warning tied to its blockbuster obesity ...

The appointment came shortly after Novo slashed its financial forecast, predicting this year’s sales will grow 8% to 14%, ...

Novo Nordisk said it expects weaker sales growth of its popular weight-loss drug Wegovy due to competition from copycat drugs ...

Thousands find weight loss relief on Zepbound. Now, they face a choice: Try a different medicine that may have adverse side effects or stop treatment.

Danish leader will face a challenging landscape among competitors ...

Novo Nordisk on Tuesday slashed its outlook for 2025 sales growth and said it had appointed veteran insider Maziar Mike ...

Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic ...

Novo Nordisk ( NVO) continued its downward spiral and fell 3.8% in premarket trade, a day after the Danish drugmaker slashed ...